EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke

Ruth D Lee, Yi-Je Chen, Hai M Nguyen, Latika Singh, Connor J Dietrich, Benjamin R Pyles, Yanjun Cui, Jonathan R Weinstein, Heike Wulff

Translational Stroke Research · 2024

DOI: 10.1007/s12975-023-01152-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Stroke Research, 2024. Verfasst von Ruth D Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA. Hauptthemen laut MEDLINE: Intermediate-Conductance Calcium-Activated Potassium Channels, Ischemic Stroke, Mice, Inbred C57BL. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Senicapoc, a small molecule inhibitor of the calcium-activated potassium channel KCa3.1, was safe and well-tolerated in clinical trials for sickle cell anemia. We previously reported proof-of-concept data suggesting that both pharmacological inhibition and genetic deletion of KCa3.1 reduces infarction and improves neurologic recovery in rodents by attenuating neuroinflammation. Here we evaluated the potential of repurposing senicapoc for ischemic stroke. In cultured microglia, senicapoc inhibited KCa3.1 currents with an IC 50 of 7 nM, reduced Ca 2+ signaling induced by the purinergic agonist ATP, suppressed expression of pro-inflammatory cytokines and enzymes (iNOS and COX-2), and prevented induction of the inflammasome component NLRP3 . When transient middle cerebral artery occlusion (tMCAO, 60 min) was induced in male C57BL/6 J mice, twice daily administration of senicapoc at 10 and 40 mg/kg starting 12 h after reperfusion dose-dependently reduced infarct area determined by T2-weighted magnetic resonance imaging (MRI) and improved neurological deficit on day 8. Ultra-high-performance liquid chromatography/mass spectrometry analysis of total and free brain concentrations demonstrated sufficient KCa3.1 target engagement. Senicapoc treatment significantly reduced microglia/macrophage and T cell infiltration and activation and attenuated neuronal death. A different treatment paradigm with senicapoc started at 3 h and MRI on day 3 and day 8 revealed that senicapoc reduces secondary infarct growth and suppresses expression of inflammation markers, including T cell cytokines in the brain. Lastly, we demonstrated that senicapoc does not impair the proteolytic activity of tissue plasminogen activator (tPA) in vitro. We suggest that senicapoc could be repurposed as an adjunctive immunocytoprotective agent for combination with reperfusion therapy for ischemic stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intermediate-Conductance Calcium-Activated Potassium ChannelsIschemic StrokeMice, Inbred C57BLAnimalsMaleMiceMicrogliaDrug RepositioningInfarction, Middle Cerebral ArteryAcetamidesPotassium Channel BlockersTriphenylmethyl Compounds

Stichwörter der Autor:innen

Ischemic strokeKCa3.1Microglia activationMiddle cerebral artery occlusionNeuroinflammationSenicapoc

Substanzen

Intermediate-Conductance Calcium-Activated Potassium ChannelsAcetamidesPotassium Channel BlockersTriphenylmethyl CompoundssenicapocKcnn4 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA.
  • Animal Models Core, Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA.
  • Department of Neurology, School of Medicine, University of Washington, Seattle, WA, 98195, USA.
  • Department of Pharmacology, School of Medicine, University of California, Davis, CA, 95616, USA. hwulff@ucdavis.edu.

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Lee, R. D., Chen, Y. J., Nguyen, H. M., Singh, L., Dietrich, C. J., Pyles, B. R., Cui, Y., Weinstein, J. R., & Wulff, H. (2024). Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke. Translational Stroke Research. https://doi.org/10.1007/s12975-023-01152-6

Vancouver

Lee RD, Chen YJ, Nguyen HM, Singh L, Dietrich CJ, Pyles BR, et al. Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke. Translational Stroke Research. 2024. doi:10.1007/s12975-023-01152-6

BibTeX
@article{Lee2024,
  author = {Lee, Ruth D and Chen, Yi-Je and Nguyen, Hai M and Singh, Latika and Dietrich, Connor J and Pyles, Benjamin R and Cui, Yanjun and Weinstein, Jonathan R and Wulff, Heike},
  title = {Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke},
  journal = {Translational Stroke Research},
  year = {2024},
  doi = {10.1007/s12975-023-01152-6}
}
Kostenlos starten →